News

PharmaMar has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the use of Aplidin (plitidepsin) in combination with Decadron (dexamethasone, an…

The Multiple Myeloma Research Foundation (MMRF) and the Memorial Sloan Kettering Cancer Center  are collaborating to launch a new clinical trial studying minimal…

The association between excess body fat and increased risk of various cancers is an undisputed fact. Now, the findings of a working group from the International…

Minimal residual disease, a measurement that shows a low level of disease detected, should be used as an endpoint in myeloma clinical trials, a study…

Janssen Biotech has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand Darzalex (daratumumab) to include…

Patients with heavily treated multiple myeloma have promising response rates when treated with a combination of selinexor (KPT-330) and low-dose dexamethasone, according to the results…

With advances in treatment for multiple myeloma, some studies have reported improved survival rates, especially among young white patients and, to a lesser extent, in patients…

Adding Darzalex (daratumumab) to the treatment of multiple myeloma with Velcade (bortezomib) and dexamethasone significantly improved progression-free survival in a clinical trial of patients who…

Empliciti (elotuzumab), a monoclonal antibody, is approved in both the U.S. and Europe as a treatment, in combination with Revlimid (lenalidomide) and Decatron (dexamethasone), for multiple myeloma patients who…

Juno Therapeutics and privately held biotech Eureka Therapeutics have entered into an immunotherapy development partnership with Memorial Sloan Kettering Cancer Center…